Galectin 3

An inhaled potent thiodigalactoside galectin-3 inhibitor appeared well-tolerated among patients with COVID-19 pneumonitis, according to study results published in American Journal of Respiratory and Critical Care Medicine.

Galectin-3 interacted with risk for fatal CV events associated with aldosterone in patients referred for coronary angiography, according to a study published in The American Journal of Cardiology.